Petra M Pöllänen1,2, Johanna Lempainen3, Antti-Pekka Laine3, Jorma Toppari4, Riitta Veijola5, Paula Vähäsalo5, Jorma Ilonen3, Heli Siljander1,2, Mikael Knip6,7,8,9. 1. Children's Hospital, University of Helsinki and Helsinki University Hospital, P.O. Box 22, FI-00014, Helsinki, Finland. 2. Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland. 3. Immunogenetics Laboratory, University of Turku and Turku University Hospital, Turku, Finland. 4. Department of Pediatrics, University of Turku and Turku University Hospital, Turku, Finland. 5. Department of Pediatrics, PEDEGO Research Group, Medical Research Center, Oulu University Hospital and University of Oulu, Oulu, Finland. 6. Children's Hospital, University of Helsinki and Helsinki University Hospital, P.O. Box 22, FI-00014, Helsinki, Finland. mikael.knip@helsinki.fi. 7. Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland. mikael.knip@helsinki.fi. 8. Tampere Center for Child Health Research, Tampere University Hospital, Tampere, Finland. mikael.knip@helsinki.fi. 9. Folkhälsan Research Center, Helsinki, Finland. mikael.knip@helsinki.fi.
Abstract
AIMS/HYPOTHESIS: In this study, we aimed to characterise rapid progressors to type 1 diabetes among children recruited from the general population, on the basis of HLA-conferred disease susceptibility. METHODS: We monitored 7410 HLA-predisposed children participating in the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) study for the development of beta cell autoimmunity and type 1 diabetes from birth over a median follow-up time of 16.2 years (range 0.9-21.1 years). Islet cell antibodies (ICA) and autoantibodies to insulin (IAA), GAD (GADA) and islet antigen 2 (IA-2A) were assessed as markers of beta cell autoimmunity. Rapid progression was defined as progression to clinical type 1 diabetes within 1.5 years of autoantibody seroconversion. We analysed the association between rapid progression and demographic and autoantibody characteristics as well as genetic markers, including 25 non-HLA SNPs predisposing to type 1 diabetes. RESULTS: Altogether, 1550 children (21%) tested positive for at least one diabetes-associated autoantibody in at least two samples, and 248 (16%) of seroconverters progressed to type 1 diabetes by the end of 2015. The median time from seroconversion to diagnosis was 0.51 years in rapid progressors (n = 42, 17%) and 5.4 years in slower progressors. Rapid progression was observed both among young (<5 years) and early pubertal children (>7 years), resulting in a double-peak distribution of seroconversion age. Compared with slower progressors, rapid progressors had a higher frequency of positivity for multiple (≥2) autoantibodies and had higher titres of ICA, IAA and IA-2A at seroconversion, and there was a higher prevalence of the secretor genotype in the FUT2 gene among those carrying the high-risk HLA genotype. Compared with autoantibody-positive non-progressors, rapid progressors were younger, were more likely to carry the high-risk HLA genotype and a predisposing SNP in the PTPN22 gene, had higher frequency of ICA, IAA, GADA and IA-2A positivity and multipositivity, and had higher titres of all four autoantibodies at seroconversion. CONCLUSIONS/ INTERPRETATION: At seroconversion, individuals with rapid progression to type 1 diabetes were characterised by a younger age, higher autoantibody titres, positivity for multiple autoantibodies and higher prevalence of a FUT2 SNP. The double-peak profile for seroconversion age among the rapid progressors demonstrates for the first time that rapid progression may take place not only in young children but also in children in early puberty. Rapid progressors might benefit from careful clinical follow-up and early preventive measures.
AIMS/HYPOTHESIS: In this study, we aimed to characterise rapid progressors to type 1 diabetes among children recruited from the general population, on the basis of HLA-conferred disease susceptibility. METHODS: We monitored 7410 HLA-predisposed children participating in the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) study for the development of beta cell autoimmunity and type 1 diabetes from birth over a median follow-up time of 16.2 years (range 0.9-21.1 years). Islet cell antibodies (ICA) and autoantibodies to insulin (IAA), GAD (GADA) and islet antigen 2 (IA-2A) were assessed as markers of beta cell autoimmunity. Rapid progression was defined as progression to clinical type 1 diabetes within 1.5 years of autoantibody seroconversion. We analysed the association between rapid progression and demographic and autoantibody characteristics as well as genetic markers, including 25 non-HLA SNPs predisposing to type 1 diabetes. RESULTS: Altogether, 1550 children (21%) tested positive for at least one diabetes-associated autoantibody in at least two samples, and 248 (16%) of seroconverters progressed to type 1 diabetes by the end of 2015. The median time from seroconversion to diagnosis was 0.51 years in rapid progressors (n = 42, 17%) and 5.4 years in slower progressors. Rapid progression was observed both among young (<5 years) and early pubertal children (>7 years), resulting in a double-peak distribution of seroconversion age. Compared with slower progressors, rapid progressors had a higher frequency of positivity for multiple (≥2) autoantibodies and had higher titres of ICA, IAA and IA-2A at seroconversion, and there was a higher prevalence of the secretor genotype in the FUT2 gene among those carrying the high-risk HLA genotype. Compared with autoantibody-positive non-progressors, rapid progressors were younger, were more likely to carry the high-risk HLA genotype and a predisposing SNP in the PTPN22 gene, had higher frequency of ICA, IAA, GADA and IA-2A positivity and multipositivity, and had higher titres of all four autoantibodies at seroconversion. CONCLUSIONS/ INTERPRETATION: At seroconversion, individuals with rapid progression to type 1 diabetes were characterised by a younger age, higher autoantibody titres, positivity for multiple autoantibodies and higher prevalence of a FUT2 SNP. The double-peak profile for seroconversion age among the rapid progressors demonstrates for the first time that rapid progression may take place not only in young children but also in children in early puberty. Rapid progressors might benefit from careful clinical follow-up and early preventive measures.
Authors: V Parikka; K Näntö-Salonen; M Saarinen; T Simell; J Ilonen; H Hyöty; R Veijola; M Knip; O Simell Journal: Diabetologia Date: 2012-03-23 Impact factor: 10.122
Authors: W J Riley; N K Maclaren; J Krischer; R P Spillar; J H Silverstein; D A Schatz; S Schwartz; J Malone; S Shah; C Vadheim Journal: N Engl J Med Date: 1990-10-25 Impact factor: 91.245
Authors: Kenney Ng; Vibha Anand; Harry Stavropoulos; Riitta Veijola; Jorma Toppari; Marlena Maziarz; Markus Lundgren; Kathy Waugh; Brigitte I Frohnert; Frank Martin; Olivia Lou; William Hagopian; Peter Achenbach Journal: Diabetologia Date: 2022-10-05 Impact factor: 10.460
Authors: Kenney Ng; Harry Stavropoulos; Vibha Anand; Riitta Veijola; Jorma Toppari; Marlena Maziarz; Markus Lundgren; Kathy Waugh; Brigitte I Frohnert; Frank Martin; William Hagopian; Peter Achenbach Journal: Diabetes Care Date: 2022-01-01 Impact factor: 17.152
Authors: Emily K Sims; Rachel E J Besser; Colin Dayan; Cristy Geno Rasmussen; Carla Greenbaum; Kurt J Griffin; William Hagopian; Mikael Knip; Anna E Long; Frank Martin; Chantal Mathieu; Marian Rewers; Andrea K Steck; John M Wentworth; Stephen S Rich; Olga Kordonouri; Anette-Gabriele Ziegler; Kevan C Herold Journal: Diabetes Date: 2022-04-01 Impact factor: 9.337
Authors: Petra M Pöllänen; Taina Härkönen; Jorma Ilonen; Jorma Toppari; Riitta Veijola; Heli Siljander; Mikael Knip Journal: J Clin Endocrinol Metab Date: 2022-02-17 Impact factor: 5.958
Authors: Janet M Wenzlau; James E DiLisio; Gene Barbour; Mylinh Dang; Anita C Hohenstein; Maki Nakayama; Thomas Delong; Rocky L Baker; Kathryn Haskins Journal: Front Immunol Date: 2022-08-10 Impact factor: 8.786
Authors: Laura A Claessens; Joris Wesselius; Menno van Lummel; Sandra Laban; Flip Mulder; Dick Mul; Tanja Nikolic; Henk-Jan Aanstoot; Bobby P C Koeleman; Bart O Roep Journal: Diabetologia Date: 2019-11-21 Impact factor: 10.122
Authors: Andreas Beyerlein; Ezio Bonifacio; Kendra Vehik; Markus Hippich; Christiane Winkler; Brigitte I Frohnert; Andrea K Steck; William A Hagopian; Jeffrey P Krischer; Åke Lernmark; Marian J Rewers; Jin-Xiong She; Jorma Toppari; Beena Akolkar; Stephen S Rich; Anette-G Ziegler Journal: J Med Genet Date: 2018-10-04 Impact factor: 5.941